BioWorld

Dec. 8, 2005

ViroPharma Prices $150M Offer To Add To Capital, Pay Off Debt

ViroPharma Inc. is raising $150.7 million through a public offering to support business development activities and general corporate purposes, as well as to pay off a portion of the company's debt. (BioWorld Today) Read More

Antigenics Trims Work Force, Awaiting Results Of Phase III

Gene Therapy Firm Celladon Secures $30M Commitment

New MDD Report: Overview Of Cardiovascular Tech Sector

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...